Revolutionary Stem Cell Delivery Method Unlocks Potential for Regenerative Medicine
Researchers at Sana Biotechnology have developed hypoimmune pluripotent (HIP) stem cells that do not trigger an immune response from an immunologically incompatible donor. HIP cells survived unrestricted for 16 weeks in fully immunocompetent allogeneic recipients and differentiated into several lineages, whereas wild-type cells were vigorously rejected. HIP cells have implications for developing new therapies for various diseases, including cancer, heart disease, and neurological disorders. The successful approach used by Sana Biotechnology could be exactly what the scientific research community has been missing, allowing for unmatched HLAs in non-immunosuppressed patients overcomes many obstacles between the stacks of research papers illustrating the potential future of stem cell therapies and the routine application of revolutionary medicine.